Terapia fotodinámica en coriorretinopatía serosa central crónica severa

  1. J. Reche-Frutos
  2. C. Calvo-González
  3. J. Donate-López
  4. F. Sáenz-Francés-San-Baldomero
  5. I. Cerván-López
  6. J. García-Feijoó
  7. García Sánchez, Julián
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2008

Volume: 83

Issue: 1

Pages: 9-13

Type: Article

DOI: 10.4321/S0365-66912008000100004 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Objective: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). Methods: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. Results: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. Conclusions: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage.

Bibliographic References

  • Ciardella, AP, Guyer, M, Spitznas, M, Yannuzzi, LA. (2001). Retina. 3. Mosby. St Louis.
  • Spaide, RF, Campeas, L, Haas, A, Yanuzzi, LA, Fisher, YL, Guyer, DR. (1996). Central serous chorioretinopathy in younger and older adults. Ophthalmology. 103. 2070-2079
  • Schatz, H, Madeira, D, Johnson, RN, McDonald, HR. (1992). Central serous chorioretinopathy in patients 60 years of age and older. Ophthalmology. 99. 63-67
  • Schmidt-Erfurth, U, Michels, S, Barbazetto, I, Laqua, H. (2002). Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 43. 830-841
  • Taban, M, Boyer, DS, Thomas, EL, Taban, M. (2004). Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 137. 1073-1080
  • Chan, WM, Lam, DS, Lai, TY, Tam, BS, Liu, DT, Chan, CK. (2003). Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 87. 1453-1458
  • Yannuzzi, LA, Slakter, JS, Gross, NE, Spaide, RF, Costa, DL, Huang, SJ. (2003). Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 23. 288-298
  • Battaglia, Parodi M, Da Pozzo, S, Ravalico, G. (2003). Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 23. 235-237
  • Lai, TY, Chan, WM, Lam, DS. (2004). Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol. 137. 826-833
  • Lai, TY, Chan, WM, Li, H, Lai, RY, Liu, DT, Lam, DS. (2006). Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. 90. 869-874
Data source: Dialnet